Key points from article :
Life Biosciences completes a Series C financing of $82 million; raised over $158 million since its founding.
Series C financing will be used to accelerate research and development activities in the company’s three platforms.
“Our 3 platforms based on seminal research demonstrate that aging biology can be modified therapeutically,” - Jerry McLaughlin, CEO.
“We expect to initiate first-in-human studies for first drug candidate possibly as early as the end of 2022,” - McLaughlin.
Mitochondrial uncoupling platform to increase metabolic rate and decrease fat accumulation in models of obesity and NASH.
Chaperone-mediated autophagy (CMA) platform to remove unwanted proteins that accumulate during aging.
Epigenetic reprogramming platform induces the expression of three Yamanaka factors to reprogram cells to a younger state and restore cellular function.
“Life Biosciences is on the cusp of revolutionizing medicine for aging-related diseases globally,” - Mehmood Khan, Executive Chairman.
